Drug Safety Archives

Announcement

Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool

RADNOR, Pa. – September 17, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in…

CertaraSeptember 17, 2025

Blog

Clinical Trials Regulation (EU) No. 536/2014 – The Impact on Annual Safety Reporting

Stay compliant with EU rules for the pharmaceutical industry. Learn about annual safety reports and…

CertaraSeptember 5, 2025

On-Demand Webinar

ToxStudio®: In silico tools to accelerate toxicology assessments

Watch to explore ToxStudio—in silico toxicology platform designed to address key preclinical safety challenges.

CertaraAugust 19, 2025

Publication

Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…

CertaraAugust 13, 2025

Blog

Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development

Learn how our experts use concentration-QTc (C-QTc) analysis to replace costly TQT studies, streamline QT…

CertaraAugust 6, 2025

On-Demand Webinar

De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator

Watch the on-demand presentation covering how the DIDB® Concomitant Meds Navigator empowers clinical development teams…

CertaraAugust 5, 2025

On-Demand Webinar

Insights Without Animals: Leveraging Human-on-a-Chip & PBPK Modeling

CertaraJuly 29, 2025

Press Coverage

The Medicine Maker: The Biosimulation Generation

The article, The Biosimulation Generation, explores the transformative potential of biosimulation in pharmaceutical R&D as…

Danielle PillsburyJuly 1, 2025

Publication

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

Due to the highly controlled settings of clinical trials, enrolled subjects may not be fully…

CertaraJune 19, 2025

On-Demand Webinar

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Discover the Real-World Impact of Model-Based Meta-Analysis. Hear from experts, see case studies to advance…

CertaraJune 18, 2025

Drug Safety

Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool

Clinical Trials Regulation (EU) No. 536/2014 – The Impact on Annual Safety Reporting

ToxStudio®: In silico tools to accelerate toxicology assessments

Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development

De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator

Insights Without Animals: Leveraging Human-on-a-Chip & PBPK Modeling

The Medicine Maker: The Biosimulation Generation

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Newsletter sign up

Quick links

Solutions

Contact